<?xml version='1.0' encoding='utf-8'?>
<document id="24744161"><sentence text="Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors."><entity charOffset="63-74" id="DDI-PubMed.24744161.s1.e0" text="gemcitabine" /><entity charOffset="115-124" id="DDI-PubMed.24744161.s1.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.24744161.s1.e0" e2="DDI-PubMed.24744161.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24744161.s1.e0" e2="DDI-PubMed.24744161.s1.e1" /></sentence><sentence text="This Phase 1 study aimed to determine the recommended Phase 2 dose of LY2334737, an oral gemcitabine prodrug, when combined with standard dose docetaxel treatment in patients with advanced solid tumors"><entity charOffset="70-79" id="DDI-PubMed.24744161.s2.e0" text="LY2334737" /><entity charOffset="89-100" id="DDI-PubMed.24744161.s2.e1" text="gemcitabine" /><entity charOffset="143-152" id="DDI-PubMed.24744161.s2.e2" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.24744161.s2.e0" e2="DDI-PubMed.24744161.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24744161.s2.e0" e2="DDI-PubMed.24744161.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24744161.s2.e0" e2="DDI-PubMed.24744161.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24744161.s2.e1" e2="DDI-PubMed.24744161.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24744161.s2.e1" e2="DDI-PubMed.24744161.s2.e2" /></sentence><sentence text=" Pharmacokinetics (PK) and antitumor activity were additionally evaluated" /><sentence text="" /><sentence text="Patients with advanced/metastatic solid tumors received escalating doses of LY2334737 once daily (QD) for 14 days, followed by a 7-day drug-free period" /><sentence text=" Docetaxel was given at 75 mg/m(2) every 3 weeks (q3w)"><entity charOffset="1-10" id="DDI-PubMed.24744161.s6.e0" text="Docetaxel" /></sentence><sentence text=" Cycles were repeated until progressive disease (PD) or unacceptable toxicity" /><sentence text="" /><sentence text="Of 22 patients recruited, all Caucasian, 7 received an LY2334737 dose of 10 mg/day, 10 received 20 mg/day, 5 received 30 mg/day" /><sentence text=" Nineteen patients discontinued due to PD, 2 due to adverse events, 1 due to investigator decision" /><sentence text=" Dose-limiting toxicities: 2× febrile neutropenia (G3), 2× fatigue (1× G2, 1× G3), 1× neutropenia (G4)" /><sentence text=" The maximum tolerated dose (MTD) was identified to be 10 mg/day" /><sentence text=" Two patients achieved partial response, 10 patients stable disease" /><sentence text=" Enrollment was stopped after unexpected hepatic toxicities were observed with LY2334737 QD for 14 days per cycle in another study of Japanese patients" /><sentence text=" PK data were consistent with the first-in-man study of LY2334737 and did not reveal any drug-drug interaction between LY2334737 and docetaxel"><entity charOffset="133-142" id="DDI-PubMed.24744161.s15.e0" text="docetaxel" /></sentence><sentence text="" /><sentence text="Combination of LY2334737 at doses up to 30 mg/day QD for 14 days per cycle with docetaxel 75 mg/m(2) q3w resulted in an undesirable toxicity profile and a low MTD of 10 mg/day"><entity charOffset="80-89" id="DDI-PubMed.24744161.s17.e0" text="docetaxel" /></sentence><sentence text=" Alternative treatment schedules of LY2334737 should be explored" /><sentence text="" /></document>